Research progress of immunoscore

Abstract

Zhao Xinru, Zhao Yuye, Li Guohong, Kan Xuan, Niu Zuoxing. Research progress of immunoscore[J]. Journal of International Oncology, 2016, 43(10): 772-774.

［1］ Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologicbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction［J］. J Clin Oncol, 2011, 29(6): 610-618. DOI: 10.1200/JCO.2010.30.5425. ［2］孙成, 田志刚. 免疫评分:依据肿瘤组织免疫特性进行预后预测［J］. 中国肿瘤生物治疗杂志, 2015, 22(2): 177-182. DOI: 10.3872/j.issn.1007385X.2015.02.006. ［3］ Mlecnik B, Bindea G, Pagès F, et al. Tumor immunosurveillance in human cancers［J］. Cancer Metastasis Rev, 2011, 30(1): 5-12. DOI: 10.1007/s1055501192707. ［4］ Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care?［J］. Nat Rev Clin Oncol, 2012, 9(2): 119-123. DOI: 10.1038/nrclinonc.2011.157. ［5］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013. ［6］ Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)high, low, and negative colorectal cancers based on protein marker expression and molecular features［J］. J Pathol, 2011, 225(3): 336-343. DOI: 10.1002/path.2879. ［7］ Laghi L, Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer［J］. Dig Dis, 2012, 30(3): 304-309. DOI: 10.1159/000337003. ［8］ Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ′immunoscore′ in the classification of malignant tumours［J］. J Pathol, 2014, 232(2): 199-209. DOI: 10.1002/path.4287. ［9］ Ingels A, Sanchez Salas RE, Ravery V, et al. Thelper 1 immunoreaction influences survival in muscleinvasive bladder cancer: proof of concept［J］. Ecancermedicalscience, 2014, 8: 486. DOI: 10.3332/ecancer.2014.486. ［10］ Van Den Boorn JG, Hartmann G. Turning tumors into vaccines: coopting the innate immune system［J］. Immunity, 2013, 39(1): 27-37. DOI: 10.1016/j.immuni.2013.07.011. ［11］ Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer［J］. Curr Opin Immunol, 2013, 25(2): 261-267. DOI: 10.1016/j.coi.2013.03.004. ［12］ Galon J, Pagès F, Marincola FM, et al. Cancer classification using the immunoscore: a worldwide task force［J］. J Transl Med, 2012, 10(1): 205. DOI: 10.1186/1479587610205. ［13］ Fridman WH, Pagès F, SautèsFridman C, et al. The immune contexture in human tumours: impact on clinical outcome［J］. Nat Rev Cancer, 2012, 12(4): 298-306. DOI: 10.1038/nrc3245. ［14］ Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer［J］. J Transl Med, 2012, 10(1): 1. DOI: 10.1186/14795876101. ［15］ Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma［J］. Clin Cancer Res, 2013, 19(5): 1225-1231. DOI: 10.1158/10780432.CCR121630. ［16］黄莹莹, 高晨燕. 免疫法治疗肿瘤的疗效评价的思考［J］. 中国临床药理学杂志, 2015, 31(13): 1338-1340. DOI: 10.13699/j.cnki.10016821.2015.13.037. ［17］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694. ［18］ Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med, 2011, 364(26): 2517-2526. DOI: 10.1056/NEJMoa1104621. ［19］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［20］ Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer［J］. Immunity, 2013, 39(4): 782-795. DOI: 10.1016/j.immuni.2013.10.003.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments